Evidence map›Paper›PMID 28586888›Full record

Observational studyJAMA2017

Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa.

Maya Petersen, Laura Balzer, Dalsone Kwarsiima, Norton Sang, Gabriel Chamie, James Ayieko, Jane Kabami, Asiphas Owaraganise, Teri Liegler, Florence Mwangwa and 14 more

3 registry-linked trialsOpen access · greenAbstract readObservational Study
In one paragraph

Observational study in JAMA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 98 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 4 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01864603 nacompletednot on this map

Sustainable East Africa Research in Community Health

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2021Enrolled150,395ConditionsHIV, Tuberculosis, Hypertension, DiabetesArmsUniversal ART in a streamlined care model, Annual Community Health Campaigns, Targeted PrEP and Targeted testing interventions, Baseline community-based HIV and multi-disease testing
NCT01864683 no registry record found
NCT04772469 nacompletednot on this mapstarted 2021, after this paper: background citation

Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men

TypeinterventionalSponsorUniversity of California, San FranciscoRan2021 to 2023Enrolled934ConditionsHuman Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, HIV Infections, Sexually Transmitted Diseases, ViralArmsProvision of multiple self-tests, Small monetary incentives, Use of SMS/text reminders to motivate adherence to ART or PrEP
3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 4 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Community-Wide Universal HIV Test and Treat Intervention Reduces Tuberculosis Transmission in Rural Uganda: A Cluster-Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Trial
  7. Trial
  8. SEARCH Human Immunodeficiency Virus (HIV) Streamlined Treatment Intervention Reduces Mortality at a Population Level in Men With Low CD4 Counts.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Early Adopters of Human Immunodeficiency Virus Preexposure Prophylaxis in a Population-based Combination Prevention Study in Rural Kenya and Uganda.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 3 countries.

Maya PetersenSchool of Public Health, University of California, Berkeley.
Laura BalzerUniversity of California, San Francisco3Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Dalsone KwarsiimaInfectious Diseases Research Collaboration, Kampala, Uganda.
Norton SangKenya Medical Research Institute, Nairobi, Kenya.
Gabriel ChamieUniversity of California, San Francisco.
James AyiekoKenya Medical Research Institute, Nairobi, Kenya.
Jane KabamiInfectious Diseases Research Collaboration, Kampala, Uganda.
Asiphas OwaraganiseInfectious Diseases Research Collaboration, Kampala, Uganda.
Teri LieglerUniversity of California, San Francisco.
Florence MwangwaInfectious Diseases Research Collaboration, Kampala, Uganda.
Kevin KadedeKenya Medical Research Institute, Nairobi, Kenya.
Vivek JainUniversity of California, San Francisco.
Albert PlentyUniversity of California, San Francisco.
Lillian BrownUniversity of California, San Francisco.
Geoff LavoyInfectious Diseases Research Collaboration, Kampala, Uganda.
Joshua SchwabSchool of Public Health, University of California, Berkeley.
Douglas BlackUniversity of California, San Francisco.
Mark van der LaanSchool of Public Health, University of California, Berkeley.
Elizabeth A BukusiKenya Medical Research Institute, Nairobi, Kenya.
Craig R CohenUniversity of California, San Francisco.
Tamara D ClarkUniversity of California, San Francisco.
Edwin CharleboisUniversity of California, San Francisco.
Moses KamyaInfectious Diseases Research Collaboration, Kampala, Uganda6Makerere University, Kampala, Uganda.
Diane HavlirUniversity of California, San Francisco.
University of California, San Francisco · USInfectious Diseases Research Collaboration · UGKenya Medical Research Institute · KEUniversity of California, Berkeley · USMakerere University · UG

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sheri Ann Lippman · 2001 to 2026
$57.4M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
UCSF HIV Clinical Trials UnitUM1AI069502 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2012 to 2013
$10.3M
Targeted Learning using adaptive designs for HIV Epidemic control in East AfricaR01AI074345 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI PETERSEN, MAYA LIV, VANDERLAAN, MARK J · 2007 to 2023
$6.6M
NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI074345NIAID NIH HHS UM1 AI069496NIAID NIH HHS UM1 AI069502NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

importanceAntiretroviral treatment (ART) is now recommended for all HIV-positive persons. UNAIDS has set global targets to diagnose 90% of HIV-positive individuals, treat 90% of diagnosed individuals with ART, and suppress viral replication among 90% of treated individuals, for a population-level target of 73% of all HIV-positive persons with HIV viral suppression.

objectiveTo describe changes in the proportions of HIV-positive individuals with HIV viral suppression, HIV-positive individuals who had received a diagnosis, diagnosed individuals treated with ART, and treated individuals with HIV viral suppression, following implementation of a community-based testing and treatment program in rural East Africa. DESIGN, SETTING, AND

participantsObservational analysis based on interim data from 16 rural Kenyan (n = 6) and Ugandan (n = 10) intervention communities in the SEARCH Study, an ongoing cluster randomized trial. Community residents who were 15 years or older (N = 77 774) were followed up for 2 years (2013-2014 to 2015-2016). HIV serostatus and plasma HIV RNA level were measured annually at multidisease health campaigns followed by home-based testing for nonattendees. All HIV-positive individuals were offered ART using a streamlined delivery model designed to reduce structural barriers, improve patient-clinician relationships, and enhance patient knowledge and attitudes about HIV. MAIN OUTCOMES AND MEASURES: Primary outcome was viral suppression (plasma HIV RNA<500 copies/mL) among all HIV-positive individuals, assessed at baseline and after 1 and 2 years. Secondary outcomes included HIV diagnosis, ART among previously diagnosed individuals, and viral suppression among those who had initiated ART.

resultsAmong 77 774 residents (male, 45.3%; age 15-24 years, 35.1%), baseline HIV prevalence was 10.3% (7108 of 69 283 residents). The proportion of HIV-positive individuals with HIV viral suppression at baseline was 44.7% (95% CI, 43.5%-45.9%; 3464 of 7745 residents) and after 2 years of intervention was 80.2% (95% CI, 79.1%-81.2%; 5666 of 7068 residents), an increase of 35.5 percentage points (95% CI, 34.4-36.6). After 2 years, 95.9% of HIV-positive individuals had been previously diagnosed (95% CI, 95.3%-96.5%; 6780 of 7068 residents); 93.4% of those previously diagnosed had received ART (95% CI, 92.8%-94.0%; 6334 of 6780 residents); and 89.5% of those treated had achieved HIV viral suppression (95% CI, 88.6%-90.3%; 5666 of 6334 residents). CONCLUSIONS AND RELEVANCE: Among individuals with HIV in rural Kenya and Uganda, implementation of community-based testing and treatment was associated with an increased proportion of HIV-positive adults who achieved viral suppression, along with increased HIV diagnosis and initiation of antiretroviral therapy. In these communities, the UNAIDS population-level viral suppression target was exceeded within 2 years after program implementation.

trial registrationclinicaltrials.gov Identifier: NCT01864683.

Indexed as

Viral LoadAdolescentAdultAnti-Retroviral AgentsCommunity Health ServicesFemaleHIVHIV InfectionsHIV SeropositivityHumansKenyaMaleMiddle AgedRNA, ViralRural PopulationUgandaAnti-Retroviral AgentsRNA, Viral

Identifiers

PMID28586888
PMCPMC5734234
OpenAlexW2623784639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.